Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro
- PMID: 9698051
- DOI: 10.1016/s0024-3205(98)00262-8
Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro
Abstract
The hallucinogenic effects of lysergic acid diethylamide (LSD) have mainly been attributed to the interaction of this drug with the serotoninergic system, but it seems more likely that they are the result of the complex interactions of the drug with both the serotoninergic and dopaminergic systems. The aim of the present study was to investigate the functional actions of LSD at dopaminergic receptors using prolactin secretion by primary cultures of rat pituitary cells as a model. LSD produced a dose-dependent inhibition of prolactin secretion in vitro with an IC50 at 1.7x10(-9) M. This action was antagonized by spiperone but not by SKF83566 or cyproheptadine, which indicates that LSD has a specific effect on D2 dopaminergic receptors. The maximum inhibition of prolactin secretion achieved by LSD was lower than that by dopamine (60% versus 80%). Moreover, the fact that LSD at 10(-8)-10(-6) M antagonized the inhibitory effect of dopamine (10(-7) M) and bromocriptine (10(-11) M) suggests that LSD acts as a partial agonist at D2 receptors on lactotrophs in vitro. Interestingly, LSD at 10(-13)-10(-10) M, the concentrations which are 10-1000-fold lower than those required to induce direct inhibition on pituitary prolactin secretion, potentiated the dopamine (10(-10)-2.5x10(-9) M)-mediated prolactin secretion by pituitary cells in vitro. These results suggest that LSD not only interacts with dopaminergic receptors but also has a unique capacity for modulating dopaminergic transmission. These findings may offer new insights into the hallucinogenic effect of LSD.
Similar articles
-
A sensitive assay for studying dopaminergic activity in cultures of rat pituitary cells.J Pharm Pharmacol. 1997 Mar;49(3):319-21. doi: 10.1111/j.2042-7158.1997.tb06804.x. J Pharm Pharmacol. 1997. PMID: 9231354
-
Activation of D2 dopamine receptors inhibits estrogen response element-mediated estrogen receptor transactivation in rat pituitary lactotrophs.Mol Cell Endocrinol. 2013 Aug 15;375(1-2):58-67. doi: 10.1016/j.mce.2013.05.011. Epub 2013 May 20. Mol Cell Endocrinol. 2013. PMID: 23701824
-
Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors.Psychopharmacology (Berl). 1977 Aug 31;54(1):39-44. doi: 10.1007/BF00426539. Psychopharmacology (Berl). 1977. PMID: 143671
-
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.Int J Mol Sci. 2016 Nov 23;17(11):1953. doi: 10.3390/ijms17111953. Int J Mol Sci. 2016. PMID: 27886063 Free PMC article. Review.
-
Effect of oestradiol on dopamine receptors and protein kinase C activity in the rat pituitary: binding of oestradiol to pituitary membranes.Ciba Found Symp. 1990;153:156-68; discussion 168-71. doi: 10.1002/9780470513989.ch9. Ciba Found Symp. 1990. PMID: 2292210 Review.
Cited by
-
Molecular and Medical Aspects of Psychedelics.Int J Mol Sci. 2023 Dec 23;25(1):241. doi: 10.3390/ijms25010241. Int J Mol Sci. 2023. PMID: 38203411 Free PMC article. Review.
-
Biological studies of clavine alkaloids targeting CNS receptors.Front Psychiatry. 2023 Nov 21;14:1286941. doi: 10.3389/fpsyt.2023.1286941. eCollection 2023. Front Psychiatry. 2023. PMID: 38076698 Free PMC article.
-
Acute psilocybin enhances cognitive flexibility in rats.Neuropsychopharmacology. 2023 Jun;48(7):1011-1020. doi: 10.1038/s41386-023-01545-z. Epub 2023 Feb 20. Neuropsychopharmacology. 2023. PMID: 36807609 Free PMC article.
-
Acute psilocybin enhances cognitive flexibility in rats.bioRxiv [Preprint]. 2023 Jan 9:2023.01.09.523291. doi: 10.1101/2023.01.09.523291. bioRxiv. 2023. Update in: Neuropsychopharmacology. 2023 Jun;48(7):1011-1020. doi: 10.1038/s41386-023-01545-z. PMID: 36712091 Free PMC article. Updated. Preprint.
-
Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies.J Psychiatry Neurosci. 2022 Jun 15;47(3):E218-E221. doi: 10.1503/jpn.220090. Print 2022 May-Jun. J Psychiatry Neurosci. 2022. PMID: 35705203 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources